No information is available on the clinical use of inotuzumab ozogamicin during breastfeeding. Because inotuzumab is a large protein molecule with a molecular weight of 168,000 Da the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Ozogamicin (N-acetyl gamma calicheamicin) is a small-molecule that causes double-stranded DNA that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during inotuzumab ozogamicin therapy for at least 2 months after the last dose.
关于在母乳喂养期间使用奥英妥珠单抗的临床信息尚无可用资料。由于奥英妥珠单抗是一种分子量为168,000道尔顿的大蛋白质分子，其在乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收量可能极小。[2]奥佐米星（N-乙酰γ-加利车霉素）是一种小分子，可导致双链DNA，其可能进入乳汁并被婴儿吸收。由于母乳喂养的婴儿可能发生严重不良反应，制造商建议在奥英妥珠单抗治疗期间停止母乳喂养，最后一剂后至少持续2个月。
Zotero 插件